About Us

MedMelior Inc. is a life sciences company creating and clinically validating an evolving intellectual property portfolio of novel molecules and drug delivery mechanisms for clinical trials and commercialization.

Our MedMelior Team

Ahmad Doroudian, PhD

Ahmad Doroudian, PhD Chief Executive Officer

  • 20+ years experience as a Pharma CEO in finance, including M&A, and multiple IPOs, Integration of pharmaceutical operations (Whitehall Robbins, Rhone Polenc, Boehringer, Aventis)
  • Founder of Merus Labs (NASDAQ: MSLI), sold for $300 M+ in 2017
  • Acquisition, integration, tech transfer and management of branded pharmaceutical products Enablex®/Emselex®, Entrophen®, Sandomigran®, Sintrom®, Vancocin®, Zaditen®
Hooshmand Sheshbaradaran, PhD

Hooshmand Sheshbaradaran, PhD Chief Operating Officer

  • 30+ years senior pharma executive with experience in global drug development, marketing, business strategy, operations, licensing and M&A
  • Senior executive roles at Pharmacia/Pfizer, Roche, Zeneus/Cephalon, Niiki Pharma, Psioxus
  • Development of Camptosar®, Ellence®, Emcyt®, Sutent® and Vidaza®.
Moira Ong, CPA, CA

Moira Ong, CPA, CA Chief Financial Officer

  • 18+ years experience as VP of Finance & CFO in several private and public companies including Merus Labs (NASDAQ: MSLI), BetterLife Pharma (CSE: BETR)
  • Managed the integration of the supply chain management and accounting Vancocin, Enablex®/Emselex®, acquired from Novartis, by Merus Labs International Inc.
  • Previously at Grant Thornton and Deloitte
Scott Rudge, PhD

Scott Rudge, PhD CMC Head

  • Founded CMC development expert services group in 2004, has worked on over 200 projects for all molecule/therapy classes since
  • Site Director & VP Operations for FeRx; increasing management responsibility at NIST, Synergen, Amylin
  • PhD in Chemical Engineering from Purdue and author of multiple peer reviewed articles, book chapters and an award-winning textbook
Dr. Wolfgang Renz, MD

Dr. Wolfgang Renz, MD Director

  • President of International Business at Physicians Interactive.
  • Formerly served as Corporate Vice President of Business Model & Healthcare Innovation at Boehringer Ingelheim, one of the world’s largest pharmaceutical companies.
  • 10+ years involvement in developing medicines and technology to help people lead healthier, more productive lives.

Our Advisory Board

Dr. Mark Swaim, MD, PhD
Mark is editor-in-chief and founder of BioPub, a small-cap biotech investing situations analysis website with a global following. He graduated summa cum laude from University of North Carolina with a chemistry and was a rare junior-year inductee into Phi Beta Kappa. In the NIH-sponsored Medical Scientist Training Program at Duke University, he earned an MD with junior election to Alpha Omega Alpha and a PhD in biochemistry and cell biology with special distinction. He trained in categorical internal medicine at Duke, completed post-doctoral work in distintegrins at National Taiwan University (Taipei), and returned to Duke for research and clinical fellowships in gastroenterology and transplant hepatology. After serving on the faculties of Duke, where he was awarded the medical center’s highes teaching honor, and later University of Texas MD Anderson Cancer Center (Houston), where he was elected to the faculty senate, and UT Health Science Center in Houston,  he established an independent freestanding hepatology clinic and clinical research institute, leading clinical trials for a large number of pharma companies and speaking nationally on interferon therapeutics for virus hepatitis as a key opinion leader for many years. He authored more than three dozen peer-reviewed publications and chapters, over 100 abstracts, and was elected Fellow of the American College of Physicians in 2002. With an impressive record of success in biotech investing and analysis, and the growing success of BioPub, he decided to devote all energies to guiding biotech investors, analyzing investing situations, and serving as a consultant to the biotech industry.
Dr. Eleanor Fish, PhD
Dr. Fish is an accomplished scientist with focus on interferon activity against variety of viruses including Covid-19, SARA, Ebola and Zika. During the 2003 outbreak of SARS in Toronto, Dr. Fish initiated studies to investigate the therapeutic potential of interferon in SARS patients. Encouraging results have directed her group’s efforts toward examining interferon activity against a number of emerging infectious diseases. Dr. Fish is a Professor, Department of Immunology, University of Toronto, Associate Chair, International Initiatives & Collaborations, University of Toronto and Emerita Scientist, Toronto General Hospital Research Institute, University Health Network. She received a B.Sc. from the University of Manchester, U.K., an M.Phil. from King’s College, University of London, U.K. and a Ph.D. from the Institute of Medical Sciences at the University of Toronto, Canada. Dr. Fish is a Fellow of the American Academy of Microbiologists and a Fellow of the African Academy of Sciences. Dr. Fish has received many international awards acknowledging her scientific achievements and has published more than 170 peer reviewed scientific papers in international journals. She is the principle author of the most recent paper published on Friday May 15, 2020 in Frontiers of Immunology titled “Interferon-α2b Treatment for COVID-19”.
Jalid Sehouli Professor, MD, h.c.

Jalid Sehouli is a gynecologist and oncologist specializing in ovarian, peritoneal and fallopian tube cancer, as well as a university lecturer and writer.

Sehouli's specialty is experimental surgical gynecology and oncosurgery, as well as physician-patient communication (Breaking Bad News). Sehouli is co-editor of several journals and author (first, senior and co-author) of several hundred articles in national and international journals on all aspects of gynecology and focus on diagnosis, treatment and follow-up of female cancers (Gynecologic Oncology). He is principal investigator of several national and international phase I, II, III trials of targeted therapies.

  • Head of the Gynecological Tumor Center and European Competence Center for Ovarian Cancer (EKZE)
  • Surgical and cytostatic therapies of ovarian cancer (various phase I, II, III studies)
  • Principal investigator of various phase I, II, III - studies on targeted therapies, clinical care research quality of life and patient-relevant outcomes (e.g. PROMS, patient preference), monocentric, multicenter, national, European, global (ovarian, fallopian tube and peritoneal cancer, uterine cancer, cervical cancer, gynecological sarcomas)